Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that it has entered into definitive agreements with fundamental healthcare investors for the purchase and sale of 14,000,000 of its shares of common stock at a purchase price of $1.25 per share in a registered direct offering.
June 11, 2020
· 4 min read